Form 8-K CAPRICOR THERAPEUTICS, For: May 13
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Capricor Therapeutics (CAPR) PT Raised to $25 at Ladenburg Thalmann
May 14, 2024 6:46 AM EDTLadenburg Thalmann analyst Aydin Huseynov raised the price target on Capricor Therapeutics (NASDAQ: CAPR) to $25.00 (from $24.00) while maintaining a Buy rating.
The analyst comments "CAPR seems to have advanced in its regulatory negotiations with the FDA with possible rolling BLA... More
